Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B
Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy.
Acta Haematol. 2006;116(2):120-5. doi: 10.1159/000093642.
Myocardial infarction and other arterial occlusions are considered to be rare in hemophilia A. However, a systematic study of the subject has never been attempted. All case reports of myocardial infarction or other arterial occlusions have been now gathered and properly evaluated from a cardiological point of view. Thirty-six patients with myocardial infarction and 6 patients with documented cerebrovascular event were retrieved from the literature. The age of the patients varied between 7 and 79 years, with a mean of 44 years. In 16 cases, the arterial occlusion occurred in men <40 years of age. The majority of myocardial infarctions (MIs) were anterolateral (12 cases). Posterior-inferior MI was present in 6 cases whereas it was of the non-Q type in 4 patients. It was multiple in 6 cases, and in the remaining patients the type of infarction could not be determined. In 26 cases, the thrombotic event (22 myocardial infarctions and 4 ischemic cerebrovascular accidents) occurred during or after the infusion of factor VIII concentrates and, more frequently, after prothrombin complex concentrates (activated or non-activated ones) or recombinant factor VIIa preparations. In 3 cases, the vascular complication occurred after intravenous desmopressin administration. MI was fatal in 7 instances. After the event, signs and symptoms of heart failure were seen as sequels in 7 patients. One patient had to undergo cardiac transplant 5 months after the MI. No death occurred after ischemic cerebrovascular accidents. Since not all hemophilia patients develop inhibitors and therefore are not usually treated with activated concentrates, this series of patients is somewhat biased and does not allow general conclusions. The high prevalence of MI and other arterial complications which occurred after transfusion therapy, usually in patients with inhibitors, clearly indicates the need for a careful evaluation of the appropriate therapeutic approach in each single patient.
心肌梗死和其他动脉闭塞在甲型血友病中被认为较为罕见。然而,从未有人尝试对该主题进行系统研究。目前已从心脏病学角度收集并妥善评估了所有关于心肌梗死或其他动脉闭塞的病例报告。从文献中检索出36例心肌梗死患者和6例有记录的脑血管事件患者。患者年龄在7岁至79岁之间,平均年龄为44岁。16例中,动脉闭塞发生在40岁以下男性。大多数心肌梗死(MI)为前侧壁(12例)。下后壁心肌梗死有6例,其中4例为非Q波型。6例为多发性,其余患者梗死类型无法确定。26例中,血栓形成事件(22例心肌梗死和4例缺血性脑血管意外)发生在输注凝血因子VIII浓缩物期间或之后,更常见于输注凝血酶原复合物浓缩物(活化或未活化)或重组凝血因子VIIa制剂之后。3例中,血管并发症发生在静脉注射去氨加压素之后。7例心肌梗死患者死亡。事件发生后,7例患者出现心力衰竭的体征和症状。1例患者在心肌梗死后5个月不得不接受心脏移植。缺血性脑血管意外后无死亡病例。由于并非所有血友病患者都会产生抑制剂,因此通常不使用活化浓缩物治疗,这一系列患者存在一定偏差,无法得出一般性结论。输血治疗后发生的心肌梗死和其他动脉并发症的高发生率,通常见于有抑制剂的患者,这清楚地表明需要对每例患者的适当治疗方法进行仔细评估。